Krazati (Adagrasib)

Adagrasib, the active ingredient in Krazati, is a KRAS G12C inhibitor presented as an oral tablet for oral use. It targets KRAS G12C‑mutated non‑small cell lung cancer in adult patients. The product is authorized for distribution within the European Union and is manufactured under strict quality standards.

GNH USA supplies Krazati as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialty pharmacies worldwide, ensuring reliable access to this targeted therapy. Our distribution network adheres to all regulatory requirements and provides comprehensive support for product handling.

Krazati (adagrasib) is a targeted therapy that acts on tumors harboring the KRAS G12C mutation, a driver alteration found in a subset of non‑small cell lung cancers. By selectively binding to the mutant protein, the drug blocks downstream signaling pathways that promote cancer cell proliferation and survival, providing a disease‑modifying option for affected patients.

KRAS G12C‑mutated NSCLC: treatment aims to reduce tumor burden, delay disease progression, and improve overall survival outcomes in adult patients with advanced disease.

Adagrasib may cause a range of adverse reactions, some of which are common and others that are serious or rare.

Common Side Effects: - Nausea - Diarrhea - Fatigue - Decreased appetite - Vomiting - Constipation

Serious or Rare Side Effects: - Elevated liver enzymes (ALT/AST) - Interstitial lung disease or pneumonitis - Cardiac arrhythmias - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic failure - Thromboembolic events

When using Krazati, several safety considerations should be observed. - Monitor liver function: perform regular ALT/AST assessments. - Assess cardiac status: obtain baseline ECG and monitor for arrhythmias. - Evaluate renal function: consider dose adjustment in severe impairment. - Review concomitant medications: avoid strong CYP3A4 inducers. - Pregnancy safety unknown: avoid use unless benefits outweigh potential risks. - Store at ambient temperature: keep in the original pack, protect from moisture.

Adagrasib can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) – may markedly reduce drug exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – may increase exposure and risk of toxicity.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin) – may modestly raise plasma levels. - Proton pump inhibitors – may affect absorption, monitor efficacy. - Statins such as simvastatin – increased risk of myopathy, consider alternative lipid‑lowering agents.